Vanderbilt-Ingram Cancer Center patients treated with new FDA-approved CAR-T therapy

Vanderbilt-Ingram Cancer Center has been selected as one of the few authorized treatment centers in the United States approved to administer the first FDA- approved chimeric antigen receptor T cell (CAR-T) therapy for treatment of adult patients with a specific type of lymphoma. VICC is the only cancer center in a seven-state region of the Southeast authorized to deliver the new immunotherapy.

New cutting-edge treatment for type of pediatric leukemia offered at Monroe Carell Jr. Children’s Hospital at Vanderbilt 

HDAC3 role in B-cell development

The histone deacetylase HDAC3 is required for the maturation of B cells, white blood cells that produce antibodies.

Restore T cells to fight leukemia

Modulation of T cell metabolism thus may represent a new therapeutic avenue for leukemia patients.

First VICC cancer patient treated with new immunotherapy

For the first time, Vanderbilt-Ingram Cancer Center (VICC) investigators have used a cancer patient’s own re-engineered immune cells to treat a form of blood cancer by stimulating the immune system.

Medical staff, theater join forces to help cancer patient see ‘Star Wars’

A Vanderbilt patient who has battled leukemia for nearly five years was granted a private screening of “Star Wars: The Force Awakens,” thanks to her medical providers and a local movie theater.